Myovant Sciences (Myovant Sciences) Gross Margin % : 65.85% (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Myovant Sciences's Gross Profit for the three months ended in Dec. 2022 was $66.0 Mil. Myovant Sciences's Revenue for the three months ended in Dec. 2022 was $100.2 Mil. Therefore, Myovant Sciences's Gross Margin % for the quarter that ended in Dec. 2022 was 65.85%.

The historical rank and industry rank for Myovant Sciences's Gross Margin % or its related term are showing as below:

MYOV' s Gross Margin % Range Over the Past 10 Years
Min: 73.03 Med: 87.19 Max: 96.69
Current: 73.03

During the past 7 years, the highest Gross Margin % of Myovant Sciences was 96.69%. The lowest was 73.03%. And the median was 87.19%.

MYOV's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.655 vs MYOV: 73.03

Myovant Sciences had a gross margin of 65.85% for the quarter that ended in Dec. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Myovant Sciences was 0.00% per year.

Myovant Sciences Gross Margin % Historical Data

The historical data trend for Myovant Sciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Gross Margin % Chart

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Gross Margin %

Get a 7-Day Free Trial

96.69

77.68

Myovant Sciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Gross Margin %	Get a 7-Day Free Trial															70.01	69.18	80.32	73.90	65.85

Competitive Comparison of Myovant Sciences's Gross Margin %

For the Biotechnology subindustry, Myovant Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myovant Sciences's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Gross Margin % falls into.

Myovant Sciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Myovant Sciences's Gross Margin for the fiscal year that ended in Mar. 2022 is calculated as

Gross Margin % (A: Mar. 2022 )	=	Gross Profit (A: Mar. 2022 )	/	Revenue (A: Mar. 2022 )
	=	179.4	/	230.972
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(230.972 - 51.551)	/	230.972
	=	77.68 %

Myovant Sciences's Gross Margin for the quarter that ended in Dec. 2022 is calculated as

Gross Margin % (Q: Dec. 2022 )	=	Gross Profit (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	66	/	100.229
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(100.229 - 34.226)	/	100.229
	=	65.85 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Myovant Sciences (NYSE:MYOV) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Myovant Sciences had a gross margin of 65.85% for the quarter that ended in Dec. 2022 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Myovant Sciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek	director, officer: Principal Executive Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra	officer: Principal Financial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	officer: Principal Fin'l & Accounting	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo	director	ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957